10
Feb

Merck’s not the only big player in the hepatitis C competition to face losing bragging rights to the FDA’s “breakthrough” drug designation for a late-stage program. It turns out that Bristol-Myers Squibb, another laggard in the race to hatch new therapies for the virus, also finds its daclatasvir on the FDA’s chopping block.

…read more

Source: Breakthrough? Not anymore says FDA as Bristol-Myers joins Merck in hep C’s coach section

    

0 No comments